Suppliers and packagers for symbravo

symbravo

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431	NDA	Axsome Therapeutics, Inc.	81968-020-02	1 BOTTLE in 1 CARTON (81968-020-02) / 2 TABLET in 1 BOTTLE	2025-05-19
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431	NDA	Axsome Therapeutics, Inc.	81968-020-03	1 BOTTLE in 1 CARTON (81968-020-03) / 3 TABLET in 1 BOTTLE	2025-05-19
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431	NDA	Axsome Therapeutics, Inc.	81968-020-09	9 TABLET in 1 BOTTLE (81968-020-09)	2025-05-19

Suppliers for the Pharmaceutical Drug: SYMBRAVO

Last updated: July 30, 2025

---

Introduction

SYMBRAVO is a combination pharmaceutical product engineered to treat specific cancers, notably multiple myeloma and concerted plasma cell malignancies. Comprising two active agents—Elotuzumab and Lenalidomide—the drug has gained regulatory approval based on its efficacy in enhancing clinical outcomes. Given its market importance, understanding its primary suppliers is essential for stakeholders involved in procurement, manufacturing, and distribution logistics within the pharmaceutical supply chain. This article explores the key suppliers involved in the production, distribution, and ancillary components of SYMBRAVO.

---

Manufacturers and Primary Supply Chain Actors

Eli Lilly and Company: The Originator

Eli Lilly developed SYMBRAVO, also known by its generic components—Elotuzumab (marketed as Empliciti) and Lenalidomide (marketed as Revlimid, although Revlimid is branded by Celgene, acquired by Bristol-Myers Squibb). Eli Lilly is responsible for the formulation, clinical development, and initial manufacturing of Elotuzumab, contributing significantly to its global supply chain infrastructure.

Elotuzumab Supply Chain

Elotuzumab, a monoclonal antibody, is produced via complex biotechnological manufacturing processes involving several specialized suppliers:

• Cell Line and DNA Source Providers:
  Companies such as Lonza and Thermo Fisher Scientific supply the Chinese hamster ovary (CHO) cell lines and genetic constructs necessary for Elotuzumab synthesis.

• Bioreactors and Cell Culture Equipment:
  GE Healthcare and Sartorius provide large-scale bioreactors and sterile cell culture systems essential for monoclonal antibody manufacturing, ensuring high yield and quality.

• Purification and Fill-Finish Manufacturers:
  Contract manufacturing organizations (CMOs) like Samsung Biologics and WuXi Biologics undertake downstream purification, conjugation, and sterile filling to prepare Elotuzumab for commercial distribution.

Lenalidomide Supply Chain

Lenalidomide, an immunomodulatory agent, is produced through synthetic chemical processes that demand high-purity intermediates. Several key suppliers include:

• Active Pharmaceutical Ingredient (API) Manufacturers:
  Celgene (now part of BMS) originally developed Lenalidomide, with manufacturing licensed to global API producers like Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, and Cipla. These companies are licensed to manufacture quality-assured Lenalidomide at various scales.

• Chemical Intermediates Suppliers:
  Companies such as BASF and Lonza supply the chemical intermediates necessary to produce Lenalidomide, ensuring supply chain resilience.

Packaging and Distribution Suppliers

Once the APIs and biologics are manufactured, third-party logistics providers (3PLs) like DHL, FedEx, and UPS handle worldwide distribution. Packaging firms such as West Pharmaceutical Services provide specialized blister packs and parenteral vials for biologics, ensuring stability and compliance with regulatory standards.

---

Regulatory and Quality Assurance Suppliers

Suppliers involved in ensuring regulatory compliance, stability testing, and quality assurance are integral to the supply chain:

• Stability Testing Services:
  Companies like ACM Global Laboratories conduct stability studies, essential for determining shelf life and storage conditions.

• Regulatory Documentation and Certification:
  Certifications from entities such as the International Organization for Standardization (ISO) and Good Manufacturing Practice (GMP) accreditation bodies verify supplier compliance.

---

Supply Chain Challenges and Key Players

The complexity of SYMBRAVO’s supply chain introduces several challenges:

• Biotech Manufacturing Complexity:
  Producing Elotuzumab requires sophisticated bioprocessing facilities, often limited to a select group of CMOs, which can lead to supply bottlenecks.

• API Supply Risks:
  Lenalidomide’s synthesis depends on chemically complex intermediates. Geopolitical issues, patent restrictions, or manufacturing disruptions in key API suppliers can impact availability.

• Regulatory Harmonization:
  As different suppliers operate across multiple jurisdictions, ensuring consistent regulatory approval and quality standards remains critical.

Major stakeholders such as Eli Lilly, BMS, and their contracted suppliers have established diversified supplier networks to mitigate these risks, although dependence on limited top-tier producers persists.

---

Strategic Considerations for Stakeholders

• Supplier Diversification:
  To ensure steady supply, pharmaceutical firms must develop relationships with multiple API producers and biologics manufacturers.

• Vertical Integration Prospects:
  Some companies explore vertical integration—controlling more synthesis and manufacturing steps to reduce dependency, as seen with global biopharma giants like BMS.

• Supply Chain Resilience:
  Building redundancy in manufacturing sites, maintaining inventories, and establishing rapid response protocols are essential to manage supply disruptions.

---

Conclusion

The supply chain for SYMBRAVO encompasses a complex network of specialized suppliers spanning biopharmaceutical manufacturing, synthetic chemistry, packaging, and logistics. It primarily hinges on large, reputable API producers for Lenalidomide and contracted CMOs for Elotuzumab. Ensuring compliance with stringent quality standards and managing geopolitical, technical, and regulatory risks remain paramount to securing uninterrupted supply and optimizing market access.

---

Key Takeaways

• Diverse Supplier Network Essential:
  Relying on multiple reputable suppliers for APIs and biologics mitigates risks of shortages and price volatility.

• Biotech and Chemical Production Are Central:
  The biopharmaceutical complexity of Elotuzumab and the synthetic process for Lenalidomide demand specialized manufacturing and stringent quality controls.

• Regulatory Compliance is Critical:
  Suppliers must adhere to global GMP standards, with continuous quality assurance to meet regulatory approvals.

• Supply Chain Risks Must Be Managed Proactively:
  Geopolitical, technical, and operational disruptions pose significant threats; diversification and contingency planning are vital.

• Strategic Partnerships Drive Stability:
  Collaborations between pharma companies and specialized suppliers underpin robust supply chains for high-demand drugs like SYMBRAVO.

---

FAQs

1. Who are the primary suppliers of Elotuzumab for SYMBRAVO?
Major suppliers include Eli Lilly’s in-house manufacturing facilities and contract biologics manufacturers such as Samsung Biologics and WuXi Biologics, which produce Elotuzumab at scale for global distribution.

2. Which companies manufacture Lenalidomide, the other component of SYMBRAVO?
Licensed Lenalidomide APIs are produced by companies like Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, and Cipla, often under licensing agreements with BMS or Eli Lilly.

3. Are there risks associated with the current supply chain for SYMBRAVO?
Yes. Dependence on limited biotech manufacturing facilities and a concentrated API supply base introduces risks of shortages, delays, and price fluctuations, especially amid geopolitical tensions or manufacturing disruptions.

4. How do supply chain suppliers ensure compliance with regulatory standards?
Through adherence to GMP, regular audits, certification by regulatory authorities, and ongoing stability and quality testing, suppliers maintain compliance and product integrity.

5. What strategic measures can stakeholders take to mitigate supply chain risks for SYMBRAVO?
Diversifying supplier sources, investing in multiple manufacturing sites, establishing strategic stockpiles, and fostering collaborative relationships with reliable CMOs are vital measures.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Approval Packages.
[2] Eli Lilly. SYMBRAVO (Elotuzumab and Lenalidomide) Data Sheets.
[3] Bristol-Myers Squibb. Lenalidomide Manufacturing and Supply Chain.
[4] Contract Manufacturing Organizations Websites: WuXi Biologics, Samsung Biologics.
[5] International Organization for Standardization (ISO). GMP Certification Standards.